|
|
Post by rockstarrick on Sept 4, 2018 12:04:20 GMT -5
Anyone else see this in the release? “United Therapeutics will manufacture the long-term commercial supplies.” Does this mean that the IP for manufacturing TS is going to be shared with UTHR? I hope they button that up to be sure it doesn’t get away from them. The whole concept of Technosphere has always been “your drug our delivery”. I would think it’s more than protected with this kind of marketing strategy. The more partners the merrier !! Right ?? |
|
|
|
Post by mango on Sept 4, 2018 12:07:55 GMT -5
Wonder if MannKind is conducting research for dry powder PDE5 inhibitors
|
|
|
|
Post by akemp3000 on Sept 4, 2018 12:13:46 GMT -5
Right Rockstar. Next we need to hear about an Epi partner, migraines with RLS, the China deal and more progress on Mike's recapitalization plan. We'll also be getting various new trial results along the way. Mike, our CEO of the year, knows what he's doing and obviously knows how to juggle  |
|
|
|
Post by peppy on Sept 4, 2018 12:24:48 GMT -5
Wonder if MannKind is conducting research for dry powder PDE5 inhibitors whole threads exist on that one mango. the nil vs fil. Sildenafil, viagra etc. Tadalafil Vardenafil It may be a bit like free energy, too good for who ever to have. |
|
|
|
Post by babaoriley on Sept 4, 2018 12:47:45 GMT -5
No what would be really great.... If United Therapeutics takes a stake in mnkd. Yes, a 100% stake for $10! I'm a modest dreamer, what can I say? LOL |
|
|
|
Post by mnholdem on Sept 4, 2018 13:02:37 GMT -5
Anyone else see this in the release? “United Therapeutics will manufacture the long-term commercial supplies.” Does this mean that the IP for manufacturing TS is going to be shared with UTHR? I hope they button that up to be sure it doesn’t get away from them. Manufacturing will be licensed, not given away. |
|
|
|
Post by mnholdem on Sept 4, 2018 13:04:32 GMT -5
No what would be really great.... If United Therapeutics takes a stake in mnkd. Yes, a 100% stake for $10! I'm a modest dreamer, what can I say? LOL I always thought of you as leaning toward the immodest side, baba. |
|
|
|
Post by babaoriley on Sept 4, 2018 13:31:44 GMT -5
Yes, a 100% stake for $10! I'm a modest dreamer, what can I say? LOL I always thought of you as leaning toward the immodest side, baba. Only fiscally modest, MN, otherwise, you're all over it! |
|
|
|
Post by uvula on Sept 4, 2018 13:47:43 GMT -5
From the wiki thing someone posted we can assume 2 things:
PH is important to UT so hey aren't going to shove our drug in a corner like Sanofi did with Afrezza. And the CEO is an honorable person like Al and UT isn't going to screw their partners.
|
|
|
|
Post by mytakeonit on Sept 4, 2018 14:07:26 GMT -5
Yawn !!! Are we at the end of August yet?
|
|
|
|
Post by buyitonsale on Sept 4, 2018 14:10:44 GMT -5
"The effectiveness of the licensing and collaboration agreement is conditioned on expiration or termination
of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act."
Does this mean the money changes hands in about 30 days and there are some filing prerequisites ?
|
|
|
|
Post by tingtongtung on Sept 4, 2018 14:48:45 GMT -5
Will MikeC say something about new drug development deal in today's call? I think, he may. This deal seems to be going on for a long time, and they may have forged some more? Also, we may expect Receptor announcement soon..
I hope he floods the news with some more smaller deals, brings MNKD back in news, and gets Afrezza some free publicity. Hindsight, I should have bought even more at 1.0x :-)
|
|
|
|
Post by mnholdem on Sept 4, 2018 16:22:51 GMT -5
Mike stated that improved cash situation (indicated more $ in coming months) will enable MannKind to expand it’s pipeline. What I’d really like to hear is the start of the FDA-mandated lung safety study for Afrezza. This will be especially vital to Afrezza winning approval for pediatric use.
|
|
|
|
Post by humann on Sept 4, 2018 16:58:52 GMT -5
Happy to have a positive reason to lurk on the board today. Picked up some more shares, it's been a while!
|
|
|
|
Post by ezrasfund on Sept 4, 2018 17:00:52 GMT -5
Absolutely! What a remarkable person!
Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. Rothblatt graduated from University of California, Los Angeles with a combined law and MBA degree in 1981, then began to work in Washington, D.C., first in the field of communications satellite law, and eventually in life sciences projects like the Human Genome Project.[5] She is the founder and Chairwoman of the Board of United Therapeutics. She was also the CEO of GeoStar and the creator of SiriusXM Satellite Radio.[6] She was the top earning CEO in biopharmaceutical industry in 2018.
Rothblatt is a well-known voice for medical and pharmaceutical innovation. In 1994, motivated by her daughter being diagnosed with life-threatening pulmonary hypertension,[22] Rothblatt entered the world of the life sciences by first creating the PPH Cure Foundation and later by founding a medical biotechnology company (United Therapeutics, 1996).[16] At that time she also began studying for a Ph.D. in medical ethics at the Barts and The London School of Medicine and Dentistry, Queen Mary University of London. The degree was granted in June 2001 based upon her dissertation on the conflict between private and public interests in xenotransplantation. This thesis, defended before England's leading bioethicist John Harris, was later published by Ashgate House under the title Your Life or Mine.[23] In 2013, Rothblatt was the highest-paid female CEO in America, earning $38 million.[24] Rothblatt received a total compensation of $31,581,896 in 2014. On December 5, 2017 North Carolina State University conferred her an honorary Doctor of Sciences degree.[25] On May 11, 2010 she was awarded an honorary doctorate by Ben Gurion University of the Negev in recognition of her accomplishments in satellite communications and biotechnology.[26] In April 2008, Rothblatt was elected a Member of the American Philosophical Society.[27]
As of April 2018, Rothblatt earned a compensation package worth $37.1 million from United Therapeutics. The majority of the compensation package is for stock options.[7]
Source: en.wikipedia.org/wiki/Martine_Rothblatt
There is even more to Rothblatt's accomplishments. Before starting Geostar and satellite radio company Sirrius, she had to first help create the international legal framework that underpins all of these companies. Likewise before being creating a company that would develop the drug to save her daughter's life, she first had to advocate for the health insurance industry to pay for these expensive "orphan drugs" using the fact that insurance policies had lifetime caps on payments, but no limits on the cost of individual treatments or doses. www.forbes.com/forbes/2010/0510/second-acts-pharmaceuticals-orphan-drugs-pah-deep-breaths.html#20b148e6597a |
|
